Cancers, Vol. 12, Pages 1421: Galectins and Ovarian Cancer

Cancers, Vol. 12, Pages 1421: Galectins and Ovarian Cancer Cancers doi: 10.3390/cancers12061421 Authors: Chisa Shimada Rui Xu Linah Al-Alem Marina Stasenko David R. Spriggs Bo R. Rueda Ovarian cancer is known for its aggressive pathological features, including the capacity to undergo epithelial to mesenchymal transition, promoting angiogenesis, metastatic potential, chemoresistance, inhibiting apoptosis, immunosuppression and promoting stem-like features. Galectins, a family of glycan-binding proteins defined by a conserved carbohydrate recognition domain, can modulate many of these processes, enabling them to contribute to the pathology of ovarian cancer. Our goal herein was to review specific galectin members identified in the context of ovarian cancer, with emphasis on their association with clinical and pathological features, implied functions, diagnostic or prognostic potential and strategies being developed to disrupt their negative actions.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research